Minireview: Directed Differentiation and Encapsulation of Islet β-Cells-Recent Advances and Future Considerations

Molecular Endocrinology
Hubert M TseChad S Hunter

Abstract

Diabetes mellitus has rapidly become a 21st century epidemic with the promise to create vast economic and health burdens, if left unchecked. The 2 major forms of diabetes arise from unique causes, with outcomes being an absolute (type 1) or relative (type 2) loss of functional pancreatic islet β-cell mass. Currently, patients rely on exogenous insulin and/or other pharmacologies that restore glucose homeostasis. Although these therapies have prolonged countless lives over the decades, the striking increases in both type 1 and type 2 diabetic diagnoses worldwide suggest a need for improved treatments. To this end, islet biologists are developing cell-based therapies by which a patient's lost insulin-producing β-cell mass is replenished. Pancreatic or islet transplantation from cadaveric donors into diabetic patients has been successful, yet the functional islet demand far surpasses supply. Thus, the field has been striving toward transplantation of renewable in vitro-derived β-cells that can restore euglycemia. Challenges have been numerous, but progress over the past decade has generated much excitement. In this review we will summarize recent findings that have placed us closer than ever to β-cell replacement therapies. With t...Continue Reading

References

Sep 1, 1968·Endocrinology·D L CurryG M Grodsky
Jun 17, 1998·Genes & Development·M HebrokD A Melton
Nov 6, 1998·Science·J A ThomsonJ M Jones
Jul 23, 1999·Annals of the New York Academy of Sciences·R CalafioreP Brunetti
Mar 4, 2000·Proceedings of the National Academy of Sciences of the United States of America·G GradwohlF Guillemot
Mar 21, 2000·Genesis : the Journal of Genetics and Development·M GannonC V Wright
Apr 15, 2000·Pancreas·S ParaskevasL Rosenberg
Dec 28, 2002·Diabetes·Alexandra E ButlerPeter C Butler
Jul 25, 2003·Diabetologia·P Rorsman, E Renström
Oct 17, 2003·Genes & Development·Patrick CollombatPeter Gruss
Feb 20, 2004·Proceedings of the National Academy of Sciences of the United States of America·Taka-aki MatsuokaRoland Stein
Mar 5, 2004·Development·Atsushi KuboGordon Keller
Jun 15, 2004·Transplantation Proceedings·W CuiE L Chaikof
Apr 6, 2005·Transplantation Proceedings·R B ElliottC Bambra
Nov 1, 2005·Nature Biotechnology·Kevin A D'AmourEmmanuel E Baetge
Nov 29, 2005·Nature Biotechnology·Masahiro YasunagaShin-Ichi Nishikawa
Dec 6, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Dong Yun LeeYoungro Byun
Oct 21, 2006·Nature Biotechnology·Kevin A D'AmourEmmanuel E Baetge
Feb 13, 2007·Journal of Molecular Endocrinology·Amanda M Ackermann, Maureen Gannon
Mar 27, 2007·Xenotransplantation·Robert B ElliottChristina Buchanan
Mar 30, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·H IchiiC Ricordi
May 24, 2007·Tissue Engineering·Jonathan BeckKytai T Nguyen
Sep 6, 2007·Stem Cells and Development·Blaine W PhillipsN Ray Dunn
Sep 6, 2007·The Journal of Clinical Investigation·Tomer NirYuval Dor
Nov 22, 2007·Science·Junying YuJames A Thomson
May 17, 2008·Biochemical Society Transactions·Sigurd Lenzen
Aug 5, 2008·Genes & Development·Jennifer M Oliver-Krasinski, Doris A Stoffers

❮ Previous
Next ❯

Citations

Mar 1, 2017·International Journal of Pharmaceutics·Fernanda Zamboni, Maurice N Collins
May 10, 2018·Frontiers in Endocrinology·Jessie M Barra, Hubert M Tse
Oct 5, 2017·Frontiers in Endocrinology·Isobel C MouatMarc S Horwitz

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Current Opinion in Organ Transplantation
Juan Domínguez-BendalaCamillo Ricordi
The Mount Sinai Journal of Medicine, New York
Kathryn C Claiborn, Doris A Stoffers
Current Opinion in Investigational Drugs
Mattias Hansson, Ole D Madsen
Journal of Transplantation
Thierry BerneyAntonello Pileggi
© 2021 Meta ULC. All rights reserved